Invesco Exchange-Traded Fund Trust II has filed its latest NPORT-P report, providing insights into its financial standing as of August 31, 2026. This filing is significant as it reflects the company's ongoing commitment to transparency and regulatory compliance within the investment sector.
The NPORT-P filing, dated October 30, 2026, reveals that Invesco's total assets amount to approximately $14.76 million, while its net assets stand at about $14.52 million. This financial disclosure is crucial for investors and stakeholders as it offers a snapshot of the fund's performance and asset management strategy.
Background
Invesco Exchange-Traded Fund Trust II is an investment entity that operates within the financial services sector. The company is registered under the Central Index Key (CIK) number 0001378872 and has been active in filing various reports with the SEC. The firm is based in Downers Grove, Illinois, and has undergone name changes in the past, previously known as PowerShares Exchange-Traded Fund Trust II.
What the Filing Says
The filing indicates that as of the reporting date, Invesco's total liabilities are approximately $241,925.32, which leads to net assets of $14,515,553.96. The report emphasizes the fund's investment strategy and outlines its asset allocation, which is essential for potential investors and market analysts.
Impact
This filing may have implications for various stakeholders, including investors looking for transparency in fund performance. Additionally, the exchange-traded fund industry, characterized by its competitive nature, could see shifts in investor sentiment based on Invesco's financial disclosures. The filing may also impact competitors within the investment sector, particularly those offering similar financial products.
What's Next
The filing does not specify what happens next for Invesco Exchange-Traded Fund Trust II. However, stakeholders will likely monitor future filings for additional updates on the fund's performance and strategies.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






